CN117771289A - Traditional Chinese medicine composition for treating viral upper respiratory tract infection as well as preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating viral upper respiratory tract infection as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN117771289A CN117771289A CN202310853920.7A CN202310853920A CN117771289A CN 117771289 A CN117771289 A CN 117771289A CN 202310853920 A CN202310853920 A CN 202310853920A CN 117771289 A CN117771289 A CN 117771289A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- medicine composition
- upper respiratory
- respiratory tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 239000003814 drug Substances 0.000 title claims abstract description 75
- 206010047482 Viral upper respiratory tract infection Diseases 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 34
- 241001670235 Artemisia rupestris Species 0.000 claims abstract description 14
- 235000015784 Artemisia rupestris Nutrition 0.000 claims abstract description 13
- 235000017309 Hypericum perforatum Nutrition 0.000 claims abstract description 13
- 244000141009 Hypericum perforatum Species 0.000 claims abstract description 13
- 238000000605 extraction Methods 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 13
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 9
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 6
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 claims description 4
- QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical group O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 7
- 238000010171 animal model Methods 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 206010035664 Pneumonia Diseases 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000001269 achillea millefolium l. oil Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 231100000028 nontoxic concentration Toxicity 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003097 anti-respiratory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- -1 granulating Substances 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating viral upper respiratory tract infection, a preparation method and application thereof, wherein the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 500-800g of artemisia rupestris and 250-550g of hypericum perforatum. The traditional Chinese medicine composition is used for solving the long-term clinical application requirements, can effectively treat patients suffering from viral upper respiratory tract infection, and has good application value. The invention provides a traditional Chinese medicine composition for treating viral upper respiratory tract infection, and establishes a preparation method thereof, and the safety and effectiveness of the traditional Chinese medicine composition are verified through a plurality of animal model experiments.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines for treating viral upper respiratory tract infection, in particular to a traditional Chinese medicine composition for treating viral upper respiratory tract infection, a preparation method and application thereof.
Background
Upper respiratory tract infection, simply called upper respiratory tract infection. Over 80% of upper respiratory tract infections are infected by viruses. Viral upper respiratory tract infection has the characteristics of high incidence rate and strong infectivity, and can be developed all the year round, and more in winter and spring. Has great significance for the infection of the upper respiratory tract virus, relieving the symptoms of patients, shortening the course of the disease and reducing the death rate.
Modern medicine mainly treats viral upper respiratory tract infection by (1) early application of antiviral drugs (2) positive symptomatic treatment (3) prevention and treatment of secondary bacterial infection. However, no specific therapeutic drug exists clinically at present, and the drug has a plurality of adverse reactions, and some of the drugs have teratogenic effects, so that the use of the drugs is limited to a certain extent. The chemical drug treatment has better curative effect only on a certain virus, and has no broad-spectrum treatment effect on diseases. The traditional Chinese medicine has the characteristic of multi-target synergistic effect, can effectively prevent and treat diseases caused by various viruses, has broad-spectrum antiviral effect, and has good effect on treating viral upper respiratory tract infection.
At present, no specific medicine is available for treating viral upper respiratory tract infection, and in order to solve the clinical requirement, development of a traditional Chinese medicine composition for treating viral upper respiratory tract infection is needed.
Disclosure of Invention
The invention mainly aims to provide a traditional Chinese medicine composition for treating viral upper respiratory tract infection, a preparation method and application thereof, and aims to at least solve the problem that the traditional Chinese medicine for treating viral upper respiratory tract infection is lacking in the prior art.
In order to achieve the above object, according to one aspect of the present invention, there is provided a Chinese medicinal composition for treating viral upper respiratory tract infection, which is prepared from the following Chinese medicinal materials in parts by weight: 500-800g of artemisia rupestris and 250-550g of hypericum perforatum.
Further, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 650g of artemisia rupestris and 400g of hyperforin.
According to another aspect of the present invention, there is provided a method for preparing a Chinese medicinal composition for treating viral upper respiratory tract infection, the method for preparing the Chinese medicinal composition comprising: weighing Chinese medicinal materials according to the weight part ratio, respectively crushing the Chinese medicinal materials, and mixing to obtain a medicinal mixture; reflux-extracting the medicinal mixture with organic solvent for several times to obtain extractive solution; filtering, concentrating and drying the extract to obtain the traditional Chinese medicine composition.
Further, the organic solvent is ethanol water solution with the ethanol proportion of 50% -80%, the times of reflux extraction are 2-3 times, and the time of each reflux extraction is 1-2 hours; filtering, concentrating and drying comprises filtering the extractive solution under reduced pressure at 65deg.C under 0.08MPa, concentrating the filtered extractive solution at 60deg.C to obtain fluid extract with relative density of 1.10-1.15, and vacuum drying at 60deg.C under 0.08 MPa.
Further, the number of times of reflux extraction was 3.
According to another aspect of the invention, there is provided an application of a traditional Chinese medicine composition for treating viral upper respiratory tract infection, wherein the application is an application of the traditional Chinese medicine composition in preparing a preparation for treating viral upper respiratory tract infection.
Further, the preparation comprises a traditional Chinese medicine composition and a plurality of auxiliary materials.
Further, the preparation is an oral preparation.
Further, the preparation is in the form of capsule, tablet or granule.
Further, the viral upper respiratory infection is an upper respiratory infection caused by parainfluenza virus or respiratory syncytial virus.
The technical scheme of the invention has the advantages that: the traditional Chinese medicine composition is used for solving the long-term clinical application requirements, can effectively treat patients suffering from viral upper respiratory tract infection, and has good application value. The invention provides a traditional Chinese medicine composition for treating viral upper respiratory tract infection, and establishes a preparation method thereof, and the traditional Chinese medicine composition is produced into high-quality and high-efficiency traditional Chinese medicine products through advanced preparation process conditions, and the safety and effectiveness of the traditional Chinese medicine composition are verified through various animal model experiments.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the invention. In the drawings:
fig. 1 is a flowchart of an alternative method of preparing a traditional Chinese medicine composition for treating viral upper respiratory tract infection according to an embodiment of the present invention.
Detailed Description
It should be noted that, in the case of no conflict, the embodiments and features in the embodiments may be combined with each other. The invention will be described in detail below with reference to the drawings in connection with embodiments.
The invention provides a traditional Chinese medicine composition for treating viral upper respiratory tract infection, which is prepared from the following traditional Chinese medicinal materials in parts by weight: 500-800g of artemisia rupestris and 250-550g of hypericum perforatum.
Preferably, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 650g of artemisia rupestris and 400g of hyperforin.
Artemisia rupestris, chinese medicine name. Is the whole herb of Artemisia rupestris Artemisia rupestris L. Pungent and slightly warm in nature. Has effects of dispelling pathogenic wind, relieving exterior syndrome, invigorating stomach, resolving food stagnation, promoting blood circulation, and removing blood stasis. Can be used for treating common cold due to wind-cold, dyspepsia, traumatic injury, blood stasis, swelling, rubella, and snake bite. Dispelling wind, relieving exterior syndrome, invigorating stomach, resolving food stagnation, promoting blood circulation, and removing blood stasis.
Hyperforin, hypericum perforatum, chinese medicine. Is dry aerial part of Hypericum perforatum L. Pungent in flavor and cold in nature. Cutting in summer and autumn, and drying in shade or at low temperature. Liver soothing, qi stagnation relieving, heat clearing, dampness removing, repercussive and lactation promoting. Can be used for treating stagnation of liver-qi, depression, chest distress, joint swelling and pain, acute mastitis, and hypogalactia.
The traditional Chinese medicine composition is used for solving the long-term clinical application requirements, can effectively treat patients suffering from viral upper respiratory tract infection, and has good application value. The invention provides a traditional Chinese medicine composition for treating viral upper respiratory tract infection, and establishes a preparation method thereof, and the traditional Chinese medicine composition is produced into high-quality and high-efficiency traditional Chinese medicine products through advanced preparation process conditions, and the safety and effectiveness of the traditional Chinese medicine composition are verified through various animal model experiments.
The lung tissue and hypothalamus were removed from the-80℃cryorefrigerator, treated with high-efficiency protein lysate (PMSF and protease inhibitor added) and centrifuged to obtain protein supernatant. Detecting the viral load of the lung tissue by using an RT-PCR method; ELISA method for detecting lung tissue cytokines TNF-alpha, IL-6, IL-10 level and hypothalamic CAMP, PGE2 level; the ratio of T lymphocyte subset and B lymphocyte subset (CD4+, CD8+ T percentage) in peripheral blood is detected by flow detection, and the traditional Chinese medicine composition can be obtained by the experiment by reducing the contents of inflammatory factors TNF-alpha, IL-6 and IL-10 of lung tissue, reducing the contents of CAMP and PGE2 in hypothalamus and obviously increasing the CD4 of peripheral blood + 、CD8 + The T percentage can reduce the lung index of the infected mice, reduce the viral load in the lung tissues of the mice, and relieve the pathological damage degree of the lung and bronchus after infection, thereby achieving the purpose of treating lung inflammation caused by common respiratory tract infection pathogenic viruses such as parainfluenza virus, respiratory syncytial virus and the like.
The traditional Chinese medicine composition has clinical application for treating viral upper respiratory tract infection, and aims at two common viruses causing viral upper respiratory tract infection, and in vivo animal experiments are carried out to verify the effectiveness of the product. Animal experiments on two common viruses show that the product is effective on viral upper respiratory tract infection.
1. Therapeutic effect on mice model of pneumonia caused by parainfluenza virus (PIV-1) infection
The specific test method is as follows:
50 ICR mice are taken, the weight of each half of the ICR mice is 14+/-1 g, and each half of the ICR mice is randomly divided into 5 groups according to the weight grade, wherein the three groups are respectively a normal control group, a model control group and a high, medium and low dosage group of the traditional Chinese medicine composition, and each group is 10. In addition to the normal control group, parainfluenza virus was used to drop nasal infection, and administration was started on the day of infection, and the patients were perfused with 0.2ml/10g of the parainfluenza virus each time, 1 time a day, and 4 consecutive days, the normal control group and the model control group were perfused with distilled water under the same conditions. On day 5, each group of mice was weighed; the lung weight is dissected, lung tissue is taken for lung tissue pathology detection, and the lung index inhibition rate are calculated.
Lung index (%) =wet lung weight (g)/body weight (g) ×100%
Test results
As shown in table 1, after mice are infected with parainfluenza virus liquid, the lung index of mice in the model group is obviously increased, and compared with normal control group, the lung index of mice in the model group is obviously different (P < 0.01); the traditional Chinese medicine composition is administered at the beginning of the day of infection, after 4 days of treatment, the lung index of the three dose groups is obviously reduced, compared with the model control group, the lung index of the three dose groups is obviously different (P <0.01 and P < 0.05), and the inhibition rate of the lung index of the one-leaf anti-influenza capsule is 89%, 78% and 63% respectively.
Table 1: effects on the therapeutic effects of parainfluenza virus infection on mouse pneumonia
2. Therapeutic effects on mice model of pneumonia caused by Respiratory Syncytial Virus (RSV) infection
The specific test method is as follows:
50 BALB/C mice are taken, the weight of the BALB/C mice is 14+/-1 g, the male and female mice are divided into 5 groups at random according to the weight grade, and the three groups are respectively a normal control group, a model control group and a high, medium and low dosage group of the traditional Chinese medicine composition, and each group is 10. Nasal infection with RSV virus droplets was performed in addition to the normal control group. Administration was started on the day of infection, and each time, 0.2ml/10g of the composition was administered by gavage, 1 time a day for 4 consecutive days, and the normal control group and the model control group were administered by gavage with distilled water under the same conditions. On day 5, each group of mice was weighed; the lung weight is dissected, lung tissue is taken for lung tissue pathology detection, and the lung index inhibition rate are calculated.
Lung index (%) =wet lung weight (g)/body weight (g) ×100%
Experimental results
As shown in table 2, after mice were infected with RSV virus solution, the lung index of mice in the model group was significantly increased, and there was a significant difference (P < 0.01) compared to the normal control group; the traditional Chinese medicine composition is started to be administered on the day of infection, after 4 days of treatment, the lung index of the three dose groups is obviously reduced, and compared with a model control group, the lung index inhibition rates of the high, medium and low dose groups are 92%, 86% and 62% respectively. The result shows that the product has better treatment effect on the mouse pneumonia caused by RSV virus infection.
Table 2: effect on treatment of mouse pneumonia caused by RSV virus infection
3. In vitro parainfluenza virus (PIV-1) resistance efficacy experiment
The in vitro inhibition of parainfluenza virus PIV-1 by the traditional Chinese medicine composition is evaluated by adopting a CPE method through observing the values of TC0, TC50, IC50 and TI of the medicine. The results show that: the TC0 value of the capsule prepared by the traditional Chinese medicine composition is 0.056mg/ml, and the TC50 value is 0.039mg/ml; the capsule prepared by the traditional Chinese medicine composition under nontoxic concentration has obvious inhibition effect on Hep-2 cytopathy caused by PIV-1 virus infection in vitro.
4. In vitro anti-Respiratory Syncytial Virus (RSV) efficacy test
The in vitro inhibition effect of the capsule prepared by the traditional Chinese medicine composition on respiratory syncytial virus RSV is evaluated by adopting a CPE method. The results show that: the TC0 value of the capsule prepared by the traditional Chinese medicine composition is 0.056mg/ml, and the TC50 value is 0.039mg/ml; the capsule prepared by the traditional Chinese medicine composition under nontoxic concentration has obvious inhibition effect on Hep-2 cytopathy caused by RSV virus infection in vitro.
As shown in fig. 1, the present invention provides a preparation method of a traditional Chinese medicine composition, which comprises:
step S102: weighing Chinese medicinal materials according to the weight part ratio, respectively crushing the Chinese medicinal materials, and mixing to obtain a medicinal mixture;
step S104: reflux-extracting the medicinal mixture with organic solvent for several times to obtain extractive solution;
step S106: filtering, concentrating and drying the extract to obtain the traditional Chinese medicine composition.
The traditional Chinese medicine composition provided by the invention can be prepared into capsules, tablets and granules;
the preparation method of the capsule comprises the following steps: weighing Chinese medicinal materials according to the weight part ratio, respectively crushing the Chinese medicinal materials, and mixing to obtain a medicinal mixture; reflux-extracting the medicinal mixture with organic solvent for several times to obtain extractive solution; filtering, concentrating and drying the extract to obtain the traditional Chinese medicine composition. Concentrating and drying the obtained traditional Chinese medicine composition, adding auxiliary materials and wetting agents, uniformly stirring, granulating, finishing, drying, and filling into capsules to prepare capsules.
The preparation method of the granule comprises the following steps: weighing Chinese medicinal materials according to the weight part ratio, respectively crushing the Chinese medicinal materials, and mixing to obtain a medicinal mixture; reflux-extracting the medicinal mixture with organic solvent for several times to obtain extractive solution; filtering, concentrating and drying the extract to obtain the traditional Chinese medicine composition. Concentrating and drying the obtained traditional Chinese medicine composition, adding auxiliary materials and wetting agents, uniformly stirring, granulating, finishing, drying to obtain granules, and filling into a medicinal composite film to prepare a bag.
The preparation method of the tablet comprises the following steps: weighing Chinese medicinal materials according to the weight part ratio, respectively crushing the Chinese medicinal materials, and mixing to obtain a medicinal mixture; reflux-extracting the medicinal mixture with organic solvent for several times to obtain extractive solution; filtering, concentrating and drying the extract to obtain the traditional Chinese medicine composition. Concentrating and drying the obtained traditional Chinese medicine composition, adding a proper amount of auxiliary materials, and tabletting to obtain tablets.
The following examples of the preparation schemes illustrate the preparation methods of the traditional Chinese medicine composition provided by the invention.
Embodiment one: 600g of artemisia rupestris and 450g of hypericum perforatum are weighed, crushed and mixed, added with 8400 ml of 60% ethanol for reflux extraction for three times, each reflux extraction is carried out for 1 hour, the extract is filtered and concentrated by a vacuum concentration device, the extract particles are obtained after concentration, a proper amount of auxiliary materials are added, and the Chinese medicinal composition is obtained after granulation, and is prepared into capsules, tablets and granules.
Embodiment two: 550g of artemisia rupestris and 500g of hypericum perforatum are weighed, crushed and mixed, 10500 ml of 50% ethanol is added for reflux extraction for two times, each reflux extraction is carried out for 2 hours, the extract is filtered and then concentrated by a vacuum concentration device, the extract particles are obtained after concentration, a proper amount of auxiliary materials are added, and the traditional Chinese medicine composition is obtained after granulation, and is prepared into capsules, tablets and granules.
Embodiment III: 650g of artemisia rupestris and 400g of hypericum perforatum, crushing, mixing, adding 10500 ml of 50% ethanol, carrying out reflux extraction for three times, carrying out reflux extraction for 2 hours each time, using a 100-mesh sieve for decompression filtration at the temperature of 65 ℃ under the pressure of 0.08MPa, concentrating the filtered extracting solution to a clear paste with the relative density of 1.10-1.15 at the temperature of 60 ℃, carrying out vacuum drying on the clear paste at the temperature of 0.08MPa and 60 ℃, concentrating to obtain extract particles, adding a proper amount of auxiliary materials, granulating to obtain a traditional Chinese medicine composition, adding the auxiliary materials and a wetting agent, uniformly stirring, granulating, finishing, drying, and filling into capsules to obtain 1000 capsules.
Embodiment four: 700g of artemisia rupestris and 350g of hypericum perforatum, crushing, mixing, adding 10500 ml of 50% ethanol, carrying out reflux extraction for three times, carrying out reflux extraction for 2 hours each time, using a 100-mesh sieve for decompression filtration at the temperature of 65 ℃ under the pressure of 0.08MPa, concentrating the filtered extracting solution to obtain clear paste with the relative density of 1.10-1.15 at the temperature of 60 ℃, carrying out vacuum drying on the clear paste at the temperature of 0.08MPa and 60 ℃ to obtain extract particles, adding an appropriate amount of auxiliary materials, granulating to obtain a traditional Chinese medicine composition, adding the auxiliary materials and a wetting agent, uniformly stirring, preparing particles, granulating, finishing the particles, drying, and filling into a medicinal composite film to prepare 500 bags.
Fifth embodiment: 750g of artemisia rupestris and 300g of hypericum perforatum, crushing, mixing, adding 10500 ml of 50% ethanol, carrying out reflux extraction for three times, carrying out reflux extraction for 2 hours each time, filtering under reduced pressure by using a 100-mesh sieve at the temperature of 0.08MPa and 65 ℃, concentrating the filtered extracting solution to a clear paste with the relative density of 1.10-1.15 at the temperature of 60 ℃, carrying out vacuum drying on the clear paste at the temperature of 0.08MPa and 60 ℃, concentrating to obtain extract particles, adding a proper amount of auxiliary materials, granulating to obtain a traditional Chinese medicine composition, concentrating and drying the traditional Chinese medicine composition, adding a proper amount of auxiliary materials, and tabletting to obtain 1000 tablets.
The invention provides a traditional Chinese medicine composition for treating viral upper respiratory tract infection and a preparation method thereof, wherein the prescription of the traditional Chinese medicine composition consists of two medicinal materials of alpine yarrow herb and hypericum perforatum, wherein the proportion of the alpine yarrow herb is 40-70%, and the weight ratio of the hypericum perforatum is 30-60%. Pulverizing the medicinal materials, mixing thoroughly, extracting the mixed medicinal materials with organic solvent, preferably ethanol water solution, wherein the ethanol ratio is preferably 50% -80%, the extraction times are 2-3 times, preferably 3 times, and each time is 1-2 hours. The extraction liquid is concentrated and dried to obtain the extract, the process can effectively improve the yield of the extract from 12% to 20%, the product content is more abundant, the quality is better, and the clinical value and the application of the product are improved.
The above description is only of the preferred embodiments of the present invention and is not intended to limit the present invention, but various modifications and variations can be made to the present invention by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. The traditional Chinese medicine composition for treating viral upper respiratory tract infection is characterized by being prepared from the following traditional Chinese medicinal materials in parts by weight: 500-800g of artemisia rupestris and 250-550g of hypericum perforatum.
2. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 650g of artemisia rupestris and 400g of hyperforin.
3. A method for preparing a traditional Chinese medicine composition for treating viral upper respiratory tract infection, which is used for preparing the traditional Chinese medicine composition in claim 1 or 2, and is characterized in that the preparation method comprises the following steps:
weighing the traditional Chinese medicinal materials according to the weight parts, respectively crushing the traditional Chinese medicinal materials, and mixing to obtain a medicinal mixture;
reflux-extracting the medicinal mixture with organic solvent for several times to obtain extractive solution;
filtering, concentrating and drying the extract to obtain the traditional Chinese medicine composition.
4. A process according to claim 3, wherein,
the organic solvent is ethanol water solution with the ethanol proportion of 50% -80%, the times of reflux extraction are 2-3 times, and the time of each reflux extraction is 1-2h;
the filtering, concentrating and drying comprises the steps of filtering the extracting solution under the condition of 0.08MPa and 65 ℃ by using a 100-mesh sieve under reduced pressure, concentrating the filtered extracting solution to a clear paste with the relative density of 1.10-1.15 at 60 ℃, and vacuum drying the clear paste at the condition of 0.08MPa and 60 ℃.
5. The method according to claim 4, wherein,
the number of reflux extractions was 3.
6. Use of a traditional Chinese medicine composition for treating viral upper respiratory tract infection, in the preparation of a preparation for treating viral upper respiratory tract infection, according to any one of claims 1 or 2.
7. The use according to claim 6, wherein the formulation comprises the Chinese medicinal composition according to any one of claims 1 or 2 and a plurality of excipients.
8. The use according to claim 7, wherein the formulation is in the form of an oral formulation.
9. The use according to claim 8, wherein the formulation is in the form of a capsule, tablet, granule.
10. The use according to claim 6, wherein the viral upper respiratory infection is an upper respiratory infection caused by parainfluenza virus or respiratory syncytial virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310853920.7A CN117771289A (en) | 2023-07-12 | 2023-07-12 | Traditional Chinese medicine composition for treating viral upper respiratory tract infection as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310853920.7A CN117771289A (en) | 2023-07-12 | 2023-07-12 | Traditional Chinese medicine composition for treating viral upper respiratory tract infection as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117771289A true CN117771289A (en) | 2024-03-29 |
Family
ID=90382322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310853920.7A Pending CN117771289A (en) | 2023-07-12 | 2023-07-12 | Traditional Chinese medicine composition for treating viral upper respiratory tract infection as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117771289A (en) |
-
2023
- 2023-07-12 CN CN202310853920.7A patent/CN117771289A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2519643C2 (en) | Pharmaceutical composition containing ephedrae herba for treating bronchitis, and method for preparing it | |
| CN101049424B (en) | Medication for treating infection in respiratory system | |
| CN102068682A (en) | Chinese medicinal composition for treating digestive system diseases and preparation method thereof | |
| KR101088539B1 (en) | Chinese medicinal compositions for treating headache, formulations and processes for preparation therof | |
| CN101152449A (en) | Method of preparing traditional Chinese medicine preparation for treating tummy bug | |
| CN101485842A (en) | Method for preparing medicinal preparation from Chinese medicine for treating influenza | |
| WO2017113476A1 (en) | Traditional chinese medicine composition for treating gastritis | |
| CN117771289A (en) | Traditional Chinese medicine composition for treating viral upper respiratory tract infection as well as preparation method and application thereof | |
| CN116832077B (en) | Traditional Chinese medicine composition for treating viral pneumonia infection, preparation method and application thereof | |
| KR102358713B1 (en) | Compositions containing Acanthopanax sessiliflorum, Fagopyri Semen and Chaenomelis Fructus extracts for the Improvement of Allergic Rhinitis and Manufacturing Method Thereof | |
| CN104225287A (en) | Traditional Chinese medicine for treating wind-heat type common cold and preparation method of traditional Chinese medicine | |
| WO2017101210A1 (en) | Gastritis treating traditional chinese medicine composition preparation method and preparation | |
| CN102451401A (en) | Recipe of vitamin C lonicera and forsythia | |
| CN105147656A (en) | Application of chlorogenic acid to preparing medicine for treating allergic rhinitis | |
| CN101264162A (en) | Proprietary Chinese medicine for treating wind-cold common cold and preparation technique | |
| CN105816583B (en) | Compound medicine for treating cold and preparation method thereof | |
| CN113521206B (en) | Traditional Chinese medicine composition containing burdock | |
| CN111759901B (en) | Traditional Chinese medicine composition for treating functional abdominal pain of children and preparation method thereof | |
| WO2017113475A1 (en) | Traditional chinese medicine composition for treating gastritis | |
| CN102631553A (en) | Medicament for treating reflux esophagitis | |
| CN103127417A (en) | Drug for curing nasosinusitis and preparation method thereof | |
| CN102973906A (en) | Weiyangling and preparation method thereof | |
| CN105169009A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating viral influenza | |
| CN1220508C (en) | Medicine for curing diseases of digestive system and its preparation method | |
| CN105232991A (en) | Medicine composition for treating gastric mucosal lesion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |